Athyrium Capital Management, LP
CIK
1728001
Location
NEW YORK, NY
Portfolio Value
Micro
$3,203,848
Diversification
Highly concentrated
Filing Date
Global Rank
#7,174
/ 7,303
▼ 30
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+7.0%
Period ended 1 year ago
Filed Nov 12, 2024 · 1y
11 quarters · since Mar 2022
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+108.8%
SPY
+76.5%
Annualised alpha
+7.0%
Max drawdown
−69.6%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
1 positions · as of Sep 30, 2024 · Δ vs Jun 30, 2024Top Position
100.0%
0.0 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
10,000
Highly concentrated0
Portfolio Trend
11 quarters · across all stocks
Sector Breakdown
As of Sep 30, 2024| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $3,203,848 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
Trimmed
Positions the filer reducedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
1 positions ·
$3,203,848 total
· as of Sep 30, 2024
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PBYI |
Puma Biotechnology, Inc.
Healthcare
|
Held | 1,256,411 | $3,203,848 | 100.00% |